Proposed drug interventions for SARS CoV 2 infection


  • Pranshu Mehta Department of E. N. T., JSS Hospital, JSSAHER, Mysore, Karnataka, India
  • Bharathi M. B. Department of E. N. T., JSS Hospital, JSSAHER, Mysore, Karnataka, India



Corona virus treatment, Covid 19 drug intervention, Covid 19 treatment


As the pandemic has already taken lots of lives across the globe, there’s an urgent need for finding treatment options that might help in protection of infected people by either slowing or preventing the progression of the disease. It’s important to understand the structure of virus, the mechanism by which it enters the host cell, replicates and infects other cells causing progression of the disease. This article focuses on use of already available and approved drugs for treatment of corona virus based on their mechanism of action and the structure and the life cycle of the virus.  


Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) In: StatPearls Publishing;2020.

Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801-11.

Collins AR, Knobler RL, Powell H, Buchmeier MJ. Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell--cell fusion. Virology. 1982;119(2):358-71.

Nal B, Chan C, Kien F, Siu L, Tse J, Chu K, et al. Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E. J General Virol. 2005;86(Pt5):1423-34.

Neuman BW, Kiss G, Kunding AH, Bhella D, Baksh MF, Connelly S, et al. A structural analysis of M protein in coronavirus assembly and morphology. J Structur Biol. 2011;174(1):11-22.

Godet M, L’Haridon R, Vautherot JF, Laude H. TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions. Virology. 1992;188(2):666-75.

Nieto-Torres JL, Dediego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. PLoS pathogens. 2014;10(5):1004077.

Chang CK, Sue SC, Yu TH, Hsieh CM, Tsai CK, Chiang YC, et al. Modular organization of SARS coronavirus nucleocapsid protein. J Biomedical Scien. 2006;13(1):59-72.

Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein. J Virol. 2009;83(14):7221-34.

Kuo L, Masters PS. Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol. 2013;87(9):5182-92.

Sturman LS, Holmes KV, Behnke J. Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid. J Virol. 1980;33(1):449-62.

Lissenberg A, Vrolijk MM, van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier PJ, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. J Virol. 2005;79(24):15054-63.

Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(14):5871-6.

Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, et al. Effect of Renin-Angiotensin System Blockage in Patients with Acute Respiratory Distress Syndrome: A Retrospective Case Control Study. Korean J Crit Care Med. 2017;32(2):154-63.

Pines A, Fisman EZ. ACE Inhibition with Moexipril. America J Cardiovascul Drugs, 2003;3(5);351-60.

Araki K, Gangappa S, Dillehay DL, Rouse BT, Larsen CP, Ahmed R. Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation. J Exp Med. 2010;207(11):2355-67.

Brierley I, Digard P, Inglis SC. Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot. Cell. 1989;57(4):537-47.

Baranov PV, Henderson CM, Anderson CB, Gesteland RF, Atkins JF, Howard MT. Programmed ribosomal frameshifting in decoding the SARS-CoV genome. Virology. 2005;332(2):498-510.

Mielech AM, Chen Y, Mesecar AD, Baker SC. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deIS Gylating activities. Virus research. 2014 Dec 19;194:184-90.

Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21-38.

Sethna PB, Hofmann MA, Brian DA. Minus-strand copies of replicating coronavirus mRNAs contain antileaders. J Virol. 1991;65(1):320-5.

Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. J Virol. 2007;81(1):20-9.

Molenkamp R, Spaan WJ. Identification of a specific interaction between the coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal. Virology. 1997;239(1):78-86.

Kuo L, Masters PS. Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol. 2013;87(9):5182-92.

Krijnse-Locker J, Ericsson M, Rottier PJM, Griffiths G. Characterization of the budding compartment of mouse hepatitis virus: Evidence that transport from the RER to the golgi complex requires only one vesicular transport step. J Cell Biol. 1994;124(1):55-70.

Tooze J, Tooze S, Warren G. Replication of coronavirus MHV-A59 in sac- cells: determination of the first site of budding of progeny virions. Europ J Cell Biol. 1984;33(2):281-93.

de Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res. 2005;64:165-230.

Bos EC, Luytjes W, van der Meulen HV, Koerten HK, Spaan WJM. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology. 1996;218(1):52-60.

Ye Y, Hogue BG. Role of the coronavirus E viroporin protein transmembrane domain in virus assembly. J Virol. 2007;81(7):3597-607.

Maeda Y, Kinoshita T. The Acidic Environment of the Golgi Is Critical for Glycosylation and Transport. Glycobiology, 2010;495-510.

Solitro AR, MacKeigan JP. Leaving the lysosome behind: novel developments in autophagy inhibition. Future Med Chem. 2016;8(1):73-86.

Chinnapaiyan S, Parira T, Dutta R, Agudelo M, Morris A, Nair M, et al. HIV Infects Bronchial Epithelium and Suppresses Components of the Mucociliary Clearance Apparatus. PLoS One. 2017;12(1):e0169161.

Calugi C, Guarna A, Trabocchi, A. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicansinhibitors. J Enzyme Inhibition and Med Chem, 2012;28(5):936-43.

Garza-Ramos G, Xiong L, Zhong P, Mankin A. Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA. J Bacteriol. 2001;183(23):6898-907.

Lott BB, Wang Y, Nakazato T. A comparative study of ribosomal proteins: linkage between amino acid distribution and ribosomal assembly. BMC Biophys. 2013;6(1):13.

McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991-3018.

Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, et al. Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry. 2004;43(20):6059-63.

Colafella KM, Uijl E, Danser J. Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches. Encyclopedia of Endocrine Diseases. 2019;523-30.

Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System. RAS. 2015;185-9.

Kis A, Toth LA, Kunos L, Vasas S, Losonczy G, Mendes E et al. The effect of airway alkalization by nebulized sodium bicarbonate on airway blood flow. Eur Respirat J. 2012;40:P2143.

Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010;65;2(2):ii5-10.

Somer M, Kallio J, Pesonen U, Pyykkö K, Huupponen R, Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000;49(6):549-54.

Mallayasamy S, Penzak SR. Pharmacogenomic Considerations in the Treatment of HIV Infection. Pharmacogenomics. 2019;227-45.

Meisel S, Shamiss A, Rosenthal T. Clinical Pharmacokinetics of Ramipril. Clinical Pharmacokinetics. 1994;26(1);7-15.

Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrobial Chemother. 1996 Jun 1;37(suppl_C):133-42.




How to Cite

Mehta, P., & M. B., B. (2020). Proposed drug interventions for SARS CoV 2 infection. International Journal of Research in Medical Sciences, 8(5), 1950–1956.



Review Articles